NEW YORK (GenomeWeb News) – Inform Genomics said today it has reached a deal with Tesaro to evaluate the risk of chemotherapy-induced nausea and vomiting in patients.

Using Inform Genomics' bioinformatics and genomic platforms, Tesaro will assess the risk of nausea and vomiting in patients receiving certain "moderately" emetogenic chemotherapy regimens and standard antiemetic therapy, without an NK-1 receptor antagonist, Inform said.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.